Cenobamate Patent Expiration
Cenobamate is Used for treating partial onset seizures through co-administration with phenobarbital and/or phenytoin. It was first introduced by Sk Life Science Inc
Cenobamate Patents
Given below is the list of patents protecting Cenobamate, along with the drug name that holds that patent and the company name owning that drug.
| Drug Used in | Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Drug Owner |
|---|---|---|---|---|
| Xcopri | US11654133 | Use of [(1R)-1-(2-chlorophenyl)-2-(tetrazol-2-yl)ethyl] carbamate in combination therapy | Jun 16, 2039 | Sk Life |
| Xcopri | US7598279 | Neurotherapeutic azole compounds | Oct 30, 2032 | Sk Life |
A patent's expiry date may change depending upon legal activities going on that patent. Critical
activities like
abandoning of a patent, term extension of a patent or amendment of its claims can increase or
decrease the life of a
patent hence affecting its expiry date and in turn affecting the generic launch date of that
drug. Tracking these
ongoing activities on a patent application helps to keep an eye on the latest developments in
the patent process of
the drug which can give an idea of how early a drug's generic could be available. The next
section provides a list
of recent legal activities on Cenobamate's patents.
Latest Legal Activities on Cenobamate's Patents
Given below is the list recent legal activities going on the following patents of Cenobamate.
| Activity | Date | Patent Number |
|---|---|---|
 | ||
| Post Issue Communication - Certificate of Correction | 20 Oct, 2025 | US7598279 |
| Email Notification | 25 Sep, 2025 | US7598279 |
| Mail Pet Dec Routed to Certificate of Corrections Branch | 24 Sep, 2025 | US7598279 |
| Mail-Record a Petition Decision of Granted to Issue Patent in Name of the Assignee | 24 Sep, 2025 | US7598279 |
| Record a Petition Decision of Granted to Issue Patent in Name of the Assignee | 23 Sep, 2025 | US7598279 |
| Pet Dec Routed to Certificate of Corrections Branch | 21 Sep, 2025 | US7598279 |
| Electronic Review Critical
| 07 Jun, 2024 | US7598279 |
| Petition Entered | 21 Mar, 2024 | US7598279 |
| Email Notification Critical
| 20 Mar, 2024 | US7598279 |
| Mail Pub Notice re 312 amendment | 20 Mar, 2024 | US7598279 |
Cenobamate's Family Patents
Explore Our Curated Drug Screens
Clinical Trials
Recent Clinical Trials on Cenobamate:
Sometimes companies keep conducting clinical trials even after the drug's approval to discover new formulations, methods of use, or new treatment indications, so they could file for additional patents or receive regulatory exclusivity extensions, such as pediatric exclusivity, potentially delaying generic competition. Based on these recent clinical trials, generic companies need to consider the potential for new intellectual property or regulatory hurdles. These strategic moves by the drug owner might delay generic substitution or lead to additional sales of the brand drug, even after patent expiry.
| Title | Lead Sponsor | Collaborators | Status | Phases |
|---|---|---|---|---|
 | ||||
| Cenobamate Open-Label Extension Study for YKP3089C025 | SK Life Science, Inc. | NA |
COMPLETED
(Jun 1, 2026)
| PHASE3 |
| A Study to Evaluate the Safety, Efficacy, and PK of ONO-2017 in Japanese Patients With POS 2 to 17 Year Olds | Ono Pharmaceutical Co., Ltd. | NA |
RECRUITING
(May 1, 2026)
| PHASE3 |